Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

被引：0

作者：

Tony S. Mok

Ying Cheng

Xiangdong Zhou

Ki Hyeong Lee

Kazuhiko Nakagawa

Seiji Niho

Alka Chawla

Rafael Rosell

Jesus Corral

Maria Rita Migliorino

Adam Pluzanski

Kay Noonan

Yiyun Tang

Malaika Pastel

Keith D. Wilner

Yi-Long Wu

机构：

[1] Chinese University of Hong Kong,State Key Laboratory of Translational Oncology, Department of Clinical Oncology

[2] Jilin Provincial Cancer Hospital,Chungbuk National University Hospital

[3] First Affiliated Hospital of Third Military Medical University,Pulmonary Oncology Unit

[4] Chungbuk National University College of Medicine,Guangdong Lung Cancer Institute

[5] Kindai University Hospital,undefined

[6] National Cancer Center Hospital East,undefined

[7] SFJ Pharmaceuticals®,undefined

[8] Catalan Institute of Oncology,undefined

[9] Hospital Universitario Virgen del Rocio,undefined

[10] San Camillo-Forlanini Hospital,undefined

[11] Maria Sklodowska-Curie National Research Institute of Oncology,undefined

[12] Pfizer Inc.,undefined

[13] Pfizer Oncology,undefined

[14] Pfizer Oncology,undefined

[15] Guangdong General Hospital and Guangdong Academy of Medical Sciences,undefined

来源：

Drugs | 2021年 / 81卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：257 / 266

页数：9

共 50 条

[21] Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer
Argiris, A
Mittal, N
LUNG CANCER, 2004, 43 (03) : 317 - 322
[22] First-line treatment for advanced non-small-cell lung cancer
Laskin, Janessa J.
Sandler, Alan B.
ONCOLOGY-NEW YORK, 2005, 19 (13): : 1671 - 1676
[23] Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation
An, Chaolun
Zhang, Jiajun
Chu, Hongjun
Gu, Chunyan
Xiao, Feng
Zhu, Fengwei
Lu, Rujian
Shi, Hai
Zhang, Hongfei
Yi, Xin
PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 763 - 768
[24] Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer
Ji Eun Shin
Hyun Ae Jung
Sehhoon Park
Jong-Mu Sun
Se-Hoon Lee
Jin Seok Ahn
Myung-Ju Ahn
Byoung Yong Shim
Scientific Reports, 15 (1)
[25] Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
Crawford, Jeffrey
Denduluri, Neelima
Patt, Debra
Jiao, Xiaolong
Morrow, Phuong Khanh
Garcia, Jacob
Barron, Richard
Lyman, Gary H.
SUPPORTIVE CARE IN CANCER, 2020, 28 (02) : 925 - 932
[26] Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
Jeffrey Crawford
Neelima Denduluri
Debra Patt
Xiaolong Jiao
Phuong Khanh Morrow
Jacob Garcia
Richard Barron
Gary H. Lyman
Supportive Care in Cancer, 2020, 28 : 925 - 932
[27] EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
Nan, Xueli
Xie, Chao
Yu, Xueyan
Liu, Jie
ONCOTARGET, 2017, 8 (43) : 75712 - 75726
[28] Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
Kim, Young Hak
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) : 692 - +
[29] Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer
Wang, Hao
Zeng, Chenxin
Li, Xin
Wang, Youjie
Li, Xinyi
Ge, Weihong
FUTURE ONCOLOGY, 2019, 15 (02) : 181 - 191
[30] Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs
Brueckl, Wolfgang
Tufman, Amanda
Huber, Rudolf Maria
EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (02) : 143 - 155

← 1 2 3 4 5 →